IL198466A - Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines - Google Patents

Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines

Info

Publication number
IL198466A
IL198466A IL198466A IL19846609A IL198466A IL 198466 A IL198466 A IL 198466A IL 198466 A IL198466 A IL 198466A IL 19846609 A IL19846609 A IL 19846609A IL 198466 A IL198466 A IL 198466A
Authority
IL
Israel
Prior art keywords
dengue fever
immunization
fever virus
vaccine
against dengue
Prior art date
Application number
IL198466A
Other languages
English (en)
Hebrew (he)
Other versions
IL198466A0 (en
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of IL198466A0 publication Critical patent/IL198466A0/en
Publication of IL198466A publication Critical patent/IL198466A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL198466A 2006-12-01 2009-04-30 Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines IL198466A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue
PCT/FR2007/052431 WO2008065315A1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (2)

Publication Number Publication Date
IL198466A0 IL198466A0 (en) 2011-08-01
IL198466A true IL198466A (en) 2014-01-30

Family

ID=38198298

Family Applications (2)

Application Number Title Priority Date Filing Date
IL198466A IL198466A (en) 2006-12-01 2009-04-30 Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines
IL230052A IL230052A0 (en) 2006-12-01 2013-12-19 A method for vaccination against 4 serotypes of dengue

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL230052A IL230052A0 (en) 2006-12-01 2013-12-19 A method for vaccination against 4 serotypes of dengue

Country Status (16)

Country Link
US (2) US7718359B2 (cg-RX-API-DMAC7.html)
EP (1) EP2099483B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269803B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090087890A (cg-RX-API-DMAC7.html)
CN (1) CN101541344A (cg-RX-API-DMAC7.html)
AR (1) AR064009A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007327367B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0718927A2 (cg-RX-API-DMAC7.html)
CA (1) CA2668570A1 (cg-RX-API-DMAC7.html)
FR (1) FR2909286B1 (cg-RX-API-DMAC7.html)
IL (2) IL198466A (cg-RX-API-DMAC7.html)
MX (1) MX2009004223A (cg-RX-API-DMAC7.html)
MY (1) MY180698A (cg-RX-API-DMAC7.html)
TW (1) TWI400249B (cg-RX-API-DMAC7.html)
WO (1) WO2008065315A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200902540B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
ES2615390T3 (es) 2008-03-05 2017-06-06 Sanofi Pasteur Proceso para estabilizar una composición de vacuna que contiene adyuvante
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
MX343172B (es) * 2009-06-01 2016-10-26 Takeda Vaccines Inc Composiciones y metodos para administracion de vacunas contra virus del dengue.
AU2010286368B2 (en) * 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
US20150196631A1 (en) 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
PE20150356A1 (es) 2012-07-24 2015-03-20 Sanofi Pasteur Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
JP2016523251A (ja) * 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． デングウイルスワクチン組成物およびその使用方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
EP3691681A1 (en) 2017-10-05 2020-08-12 Sanofi Pasteur Compositions for booster vaccination against dengu
PE20211545A1 (es) 2018-09-05 2021-08-16 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administracion de esta
CN114555113A (zh) 2019-08-16 2022-05-27 武田疫苗股份有限公司 用于预防登革热和甲型肝炎的方法
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1080370A4 (en) 1998-05-29 2003-07-30 Epimmune Inc IDENTIFICATION OF RESILIENT DR EPITOPES LARGELY REACTIVE
WO2000057910A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
ES2322327T3 (es) * 1999-03-26 2009-06-19 Walter Reed Army Institute Of Research Vacuna multivalente contra el virus del dengue.
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
EP1263965B1 (en) * 2000-02-16 2011-09-28 The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
DK1159968T3 (da) * 2000-05-30 2009-02-23 Univ Mahidol Attenuerede stammer af Dengue-virus og deres anvendelse i en vaccinesammensætning
WO2003101397A2 (en) * 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
BRPI0408774A (pt) * 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
ATE475706T1 (de) * 2005-06-17 2010-08-15 Sanofi Pasteur Abgeschwächter dengue-serotyp-2-stamm
JP5227172B2 (ja) * 2005-08-10 2013-07-03 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー デングウイルス感染に対するワクチン接種
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.

Also Published As

Publication number Publication date
US7718359B2 (en) 2010-05-18
CN101541344A (zh) 2009-09-23
FR2909286A1 (fr) 2008-06-06
AU2007327367B2 (en) 2013-05-09
MX2009004223A (es) 2009-04-30
IL230052A0 (en) 2014-01-30
JP2010511022A (ja) 2010-04-08
AU2007327367A1 (en) 2008-06-05
TWI400249B (zh) 2013-07-01
TW200829599A (en) 2008-07-16
MY180698A (en) 2020-12-07
EP2099483A1 (fr) 2009-09-16
EP2099483B1 (fr) 2013-12-25
US20080131460A1 (en) 2008-06-05
CA2668570A1 (en) 2008-06-05
IL198466A0 (en) 2011-08-01
BRPI0718927A2 (pt) 2014-04-08
WO2008065315A1 (fr) 2008-06-05
AR064009A1 (es) 2009-03-04
KR20090087890A (ko) 2009-08-18
ZA200902540B (en) 2010-07-28
JP5269803B2 (ja) 2013-08-21
US20100239612A1 (en) 2010-09-23
FR2909286B1 (fr) 2012-06-08

Similar Documents

Publication Publication Date Title
IL198466A (en) Use of dengue fever vaccines to produce a single-value vaccine and four-value vaccine to vaccinate against dengue fever virus and vaccine kits against dengue fever containing these vaccines
IL206156A0 (en) Antibodies against influenza virus and methods of use thereof
PT2121011E (pt) Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
IL200859A (en) Dosage antidote for use in a person with influenza antigen or antigenic drug in combination with auxiliary emulsion oil in water and various related aspects thereof
ZA200800505B (en) Modified influenza virus for monitoring and improving vaccine efficiency
IL248607A (en) Methods and compositions for immunization against virus
AP2008004625A0 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
EP2139515A4 (en) WAXED VIRUSES SUITABLE FOR VACCINES
ZA200802892B (en) Vaccines and methods to treat canine influenza
ZA200909173B (en) Emulsion vaccine compositions comprising antigen and adjuvant in the aqueous phase
IL190775A0 (en) Influenza virus-like particles and vaccines containing the same
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
EP1793850A4 (en) ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
IL200432A (en) Human antibodies against hepatitis C virus and their uses
EP1984388A4 (en) HPV ANTIGENES, VACCINE COMPOSITIONS AND RELATED METHODS
GB2451216B (en) A stabilised vaccine composition comprising a viral antigen, HSA and a hydrolysed protein
EP2170382A4 (en) ATTENUATED INFLUENZA VIRUS AND LIVE VACCINE CONTAINING IT
PT2393496T (pt) Vacinas melhoradas para vírus do papiloma humano e métodos para utilização das mesmas
EP2010210A4 (en) VACCINE AGAINST BIRD FLUID AND METHOD OF APPLICATION THEREFOR
SG2014014385A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
BRPI0811499A2 (pt) Métodos para purificar um vírus ou antígeno viral, e para preparar uma vacina contra um vírus ou antígeno viral.
ZA200809056B (en) Influenza virus vaccine
ZA200905952B (en) Lyophilized preparation comprising influenza vaccine,and method for preparation thereof
ATE490782T1 (de) Chimäre vakzine-antigene gegen das klassische schweinefieber-virus
ZA201004337B (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing the same

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees